Company: DARE
Filing Date: 2025-04-24
Form Type: ARS
Source: 0001401914-25-000018
Chunk: 318

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: ARS
Chunk 318
---
 under the award of approximately $0.2 million during the grant period which ended in July 2023. No further funds are available under this award for the Phase I segment. In December 2023, the Company received a notice of award of approximately $2.0 million for the "Phase II" segment of the project. The Company recorded credits to research and development expense for costs related to the NICHD award of approximately $0.7 million for the year ended December 31, 2024. The Company recorded a receivable of approximately $0.1 million at December 31, 2024 for expenses incurred through such date that it believes are eligible for reimbursement under the grant. DARE-LARC1 In September 2021, the Company received a notice of award from NICHD to support the development of DARE-LARC1. The award in the amount of approximately $0.3 million was used to explore device insertion and removal in nonclinical studies. The Company recorded credits to research and development expense of approximately $32,000 for costs related to the NICHD award for the year ended December 31, 2023. The Company received aggregate reimbursements under the NICHD award of approximately $0.3 million during the grant period, which ended in June 2023. No further funds are available under this award. DARE-204 and DARE-214 In May 2022, the Company received a notice of award from NICHD of approximately $0.2 million to support end-user research to better understand women's preferences for a long-acting injectable contraceptive method. The findings from the research will inform the Company's target product profile and guide its development priorities for DARE-204 and DARE-214. The Company recorded credits to research and development expense of approximately $0.1 million for costs related to the NICHD award for the year ended December 31, 2023. The Company received aggregate reimbursements under the NICHD award of approximately $0.2 million during the grant period, which ended in September 2023. No further funds are available under this award. DARE-PTB2 In July 2023, the Company received a notice of award from NICHD of approximately $0.4 million to support preclinical development of a potential new therapeutic for the prevention of idiopathic preterm birth. The grant funds will support activities related to the conduct and completion of proof-of-concept target validation studies in collaboration with the University of South Florida, which are to